Not true both parties agreed to an extension. Shor
Post# of 156937
(Total Views: 667)
Posted On: 01/14/2022 10:07:46 PM
Re: Evil Rabbit #115191
Not true both parties agreed to an extension. Shorts are spinning it I read the court document.
Here is the best explanation I could find from YMB. Also the court document is posted on the FB group if you want to look.
“This is nothing more than an extension of time of the deadlines while negotiations take place. The NSF dismissal is proper as the events took place prior to the purchase of Amarex by NSF. Even then the dismissal is WITHOUT prejudice meaning other claims may be brought depending on what is found in the future. Sidley would never let the “deep pocket” off the hook voluntarily if they did not already have a deal worked out in principle with Amarex. Sidley has most likely advised CYDY to make a total settlement of claims because nobody wins in litigation. This goes along with what I said when the CC was canceled. Both parties need more time to sort through everything. This definitely isn't about CYDY’s supposed inability to post the bond. If that were the case then Amarex would not agree to delay the deadline. Lawyers do not want to be hurried. The lead Defense lawyer just withdrew and new counsel is either getting up to speed or handling a settlement. The fact that this is a joint motion to the court indicates the parties are working towards resolution. Notice no request to change the other hearing date set for 2/23? Everyone can stop with the bull about CYDY not having money to pay the bond. A bond is 10% of the base price. CYDY probably wanted to delay having to pay the 10% if negotiations are moving forward. So the delay saves CYDY $650k in wasted bond cost if negotiations are successfully completed. Understand lawyers…they want settlement…trials are always risky…getting 60% of what you want by settling instead of trying for 100% is in the client’s best interest sometimes. And if Amarex has nothing to hide they would never agree to postpone the deadlines. They would want the cloud over their head removed ASAP and do everything to force CYDY to post the bond and carry out the Order. All in all…this is about what I predicted Thursday. Settlement negotiations are under way and both sides agreed to extend the deadlines by joint motion so as allow negotiations to move forward. Settlement to be announced soon.”
Here is the best explanation I could find from YMB. Also the court document is posted on the FB group if you want to look.
“This is nothing more than an extension of time of the deadlines while negotiations take place. The NSF dismissal is proper as the events took place prior to the purchase of Amarex by NSF. Even then the dismissal is WITHOUT prejudice meaning other claims may be brought depending on what is found in the future. Sidley would never let the “deep pocket” off the hook voluntarily if they did not already have a deal worked out in principle with Amarex. Sidley has most likely advised CYDY to make a total settlement of claims because nobody wins in litigation. This goes along with what I said when the CC was canceled. Both parties need more time to sort through everything. This definitely isn't about CYDY’s supposed inability to post the bond. If that were the case then Amarex would not agree to delay the deadline. Lawyers do not want to be hurried. The lead Defense lawyer just withdrew and new counsel is either getting up to speed or handling a settlement. The fact that this is a joint motion to the court indicates the parties are working towards resolution. Notice no request to change the other hearing date set for 2/23? Everyone can stop with the bull about CYDY not having money to pay the bond. A bond is 10% of the base price. CYDY probably wanted to delay having to pay the 10% if negotiations are moving forward. So the delay saves CYDY $650k in wasted bond cost if negotiations are successfully completed. Understand lawyers…they want settlement…trials are always risky…getting 60% of what you want by settling instead of trying for 100% is in the client’s best interest sometimes. And if Amarex has nothing to hide they would never agree to postpone the deadlines. They would want the cloud over their head removed ASAP and do everything to force CYDY to post the bond and carry out the Order. All in all…this is about what I predicted Thursday. Settlement negotiations are under way and both sides agreed to extend the deadlines by joint motion so as allow negotiations to move forward. Settlement to be announced soon.”
(15)
(0)CytoDyn Inc (CYDY) Stock Research Links
Daniel Rizzo
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol
[/img]https://investorshangout.com/images/MYImages/1472647104_IMG_3103.png[/img]
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
https://investorshangout.com/images/MYImages/..._3106.jpeg
https://investorshangout.com/images/MYImages/..._3107.jpeg
The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).
- Waiting…
whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……
“This isn’t conspiracy, this is criminal suppression.” - Ohm
https://www.justice.gov/usao-sdny/pr/us-attor...r-programs
https://investorshangout.com/images/MYImages/..._3015.jpeg
???? What Leronlimab Does
• Target: CCR5 receptor (the same receptor people with the CCR5Δ32 mutation lack — like the “Berlin” and “London” patients who were cured after stem cell transplants).
• Effect: By binding CCR5, leronlimab blocks HIV entry into CD4 cells.
• Trial Data:
• In combination therapy trials, ~81% of patients achieved viral loads <50 copies/mL (suppression, not cure).
• As monotherapy, some patients maintained suppression for long stretches (months), but not universally.
⸻
???? Why It Might Be Seen as a “Cure”
• In theory, if you completely block CCR5 on all relevant cells, HIV can’t infect new cells.
• If existing infected reservoirs naturally decay without replenishment, the virus could eventually vanish.
• That’s exactly what happened in the Berlin/London patients — except through stem cell transplants with CCR5Δ32 donors, not a drug.
⸻
???? Why It Hasn’t Been Called a Cure (Yet)
1. HIV Reservoirs Persist
Leronlimab blocks new infection, but it doesn’t flush latent virus from cells. Once treatment stops, those reservoirs can reignite infection.
2. CCR5-Independent Pathways
Some HIV strains use CXCR4 or dual-tropism (CCR5 + CXCR4). Leronlimab won’t stop those.
3. Clinical Conservatism
Researchers avoid using the word “cure” unless patients remain off all therapy with no viral rebound for years. Leronlimab hasn’t shown that in trials.
⸻
???? So Could It Alone Cure HIV?
• In select cases (if someone’s virus is purely CCR5-tropic and their reservoirs naturally decay): maybe.
• But in the general population, it’s unlikely as a monotherapy cure. More realistic is using it as part of a cure combo approach…
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol
[/img]https://investorshangout.com/images/MYImages/1472647104_IMG_3103.png[/img]
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
https://investorshangout.com/images/MYImages/..._3106.jpeg
https://investorshangout.com/images/MYImages/..._3107.jpeg
The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).
- Waiting… whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……
“This isn’t conspiracy, this is criminal suppression.” - Ohm
https://www.justice.gov/usao-sdny/pr/us-attor...r-programs
https://investorshangout.com/images/MYImages/..._3015.jpeg
???? What Leronlimab Does
• Target: CCR5 receptor (the same receptor people with the CCR5Δ32 mutation lack — like the “Berlin” and “London” patients who were cured after stem cell transplants).
• Effect: By binding CCR5, leronlimab blocks HIV entry into CD4 cells.
• Trial Data:
• In combination therapy trials, ~81% of patients achieved viral loads <50 copies/mL (suppression, not cure).
• As monotherapy, some patients maintained suppression for long stretches (months), but not universally.
⸻
???? Why It Might Be Seen as a “Cure”
• In theory, if you completely block CCR5 on all relevant cells, HIV can’t infect new cells.
• If existing infected reservoirs naturally decay without replenishment, the virus could eventually vanish.
• That’s exactly what happened in the Berlin/London patients — except through stem cell transplants with CCR5Δ32 donors, not a drug.
⸻
???? Why It Hasn’t Been Called a Cure (Yet)
1. HIV Reservoirs Persist
Leronlimab blocks new infection, but it doesn’t flush latent virus from cells. Once treatment stops, those reservoirs can reignite infection.
2. CCR5-Independent Pathways
Some HIV strains use CXCR4 or dual-tropism (CCR5 + CXCR4). Leronlimab won’t stop those.
3. Clinical Conservatism
Researchers avoid using the word “cure” unless patients remain off all therapy with no viral rebound for years. Leronlimab hasn’t shown that in trials.
⸻
???? So Could It Alone Cure HIV?
• In select cases (if someone’s virus is purely CCR5-tropic and their reservoirs naturally decay): maybe.
• But in the general population, it’s unlikely as a monotherapy cure. More realistic is using it as part of a cure combo approach…